Atea Pharmaceuticals Stock Story

AVIR -  USA Stock  

USD 25.03  1.02  3.92%

Atea Pharmaceuticals Stock News module provides quick insight into current market opportunities from investing in Atea Pharmaceuticals. Use historical and current headlines to determine the investment entry and exit points. Many technical investors use Atea Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Please continue to Atea Pharmaceuticals Hype Analysis, Atea Pharmaceuticals Correlation and Atea Pharmaceuticals Performance.

Search Today's Stock News 

 
Refresh
Atea Pharmaceuticals stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Atea Pharmaceuticals daily returns and investor perception about the current pice of Atea Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Acquisition by Hammond Janet Mj of 160050 shares of Atea Pharmaceuticals subject to Rule 16b-3
Filed transaction by Atea Pharmaceuticals Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Atea Pharmaceuticals insider trading alert for grant of stock option (right to buy) by Hammond Janet Mj, Chief Development Officer, on 1st of February 2021. This event was filed by Atea Pharmaceuticals Inc with SEC on 2021-02-01. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals

Other Macroaxis Stories

Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios

Atea Pharmaceuticals Fundamental Analysis

We analyze Atea Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Z Score

Z Score Comparative Analysis

Atea Pharmaceuticals is currently under evaluation in z score category among related companies. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Atea Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Atea Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Atea Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Atea Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Atea Pharmaceuticals Related Equities

EDIT
EDITEditas Medicine   6.39   
0%
50.0%
DMAC
DMACDiamedica Therapeutics   6.12   
0%
48.0%
DNLI
DNLIDenali Therapeutics   5.14   
0%
40.0%
DVAX
DVAXDynavax Technologies   4.57   
0%
36.0%
DTIL
DTILPrecision Biosciences   2.84   
0%
22.0%
EDSA
EDSAEdesa Biotech   1.63   
0%
12.0%
DRNA
DRNADicerna Pharmaceutic   1.08   
0%
8.0%
DSGN
DSGNDesign Therapeutics   0.85   
0%
6.0%
EQ
EQEquillium   5.99   
47.0%
0%
DYAI
DYAIDyadic International   12.60   
100.0%
0%
Please continue to Atea Pharmaceuticals Hype Analysis, Atea Pharmaceuticals Correlation and Atea Pharmaceuticals Performance. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.